Table 1.

Patient Characteristics

Patient
	1	2	3	4	5	6	7	8	9	10	11	12	13
Age, years	42	29	65	32	58	48	65	49	40	55	56	52	72
Sex	M	M	F	M	F	F	F	M	M	M	M	M	M
Treatment type	MUD	MUD	Mini-MUD	MUD	Mini-MUD	MUD	Mini-MUD	MUD	MUD	MUD	MUD	Sibling allogeneic	Mini-MUD
Diagnosis	PH + ALL	CML	CLL	NHL	AML	AML	MM	CML	AML	NHL	MDS	NHL	AML
ECOG	3	3	1	2	2	1	2	3	3	2	4	2	1
Graft-versus-host disease	Chronic skin, lung, liver	None	None	Chronic lung, sicca syndrome	None	None	None	Chronic lung	Chronic lung, eye, skin	Chronic liver	None	Acute skin	Pretransplantation
Prednisone >20 mg	Yes	Yes	No	No	No	Yes	No	Yes	No	Yes	Yes	Yes	No
Duration of symptoms before diagnosis	5 days	Asymptomatic	24 hours	7 days	5 days	3 days	4 days	> 1 month	10 days	Unknown	1 month	24 hours	2-3 days
Time after treatment/engraftment status	3 years/+	14 days/-	6 days/-	2 years/+	17 days/+	48 days/+	25 days/+	8 months/+	4.7 years/+	132 days/+	38 days/+	45 days/+	Pretransplantation
Pulmonary status	History of Pseudomonas pneumonia 3/04, 8/04, 3/05; 2 L O2	O2 saturation 96% on RA; chest x-ray/computed tomography changes; crackles	O2 saturation 99% on RA	History of BOOP, O2 saturation 97% on RA	O2 saturation 90%-92% on RA	O2 saturation 99% on RA	O2 saturation 96% on RA	History of cytomegalovirus pneumonia 4/05; O2 saturation 97% on RA	Concomitant infection with C. galbrata, C. guilliermondii, MRSA (BAL)	On RA	Presented with rapid-onset respiratory failure before BAL,? DAH with CMV + effusions	O2 saturation 95% on RA	O2 saturation 100% on RA
ALC	200	0	WBC 0.4	1000	200	400	500	1500	WBC 5.3 No differential	400	WBC 3.5 No differential	800	600
Ribavirin	i.v., HD, i.v. IG	No	Inhaled × 5 days, i.v. × 3 days	Inhaled × 7 days	Inhaled × 7 days	No	No	Inhaled × 7 days	Oral × 18 days, i.v. × 3 days	No	Inhaled ×x 3 days, i.v. × 7 days	No	No
Symptoms	LRTI	LRTI	LRTI	LRTI	LRTI	URTI	LRTI	LRTI	LRTI	URTI	LRTI	URTI	URTI
Outcome	Expired	Expired	Recovered	Expired	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Expired	Recovered	Recovered

BAL, Bronchoalveolar lavage, CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; AML, acute myelogenous leukemia MUD, matched unrelated donor; MM, multiple myeloma MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma.